Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00881946 Completed - Clinical trials for Hematologic Malignancies

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Start date: July 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.

NCT ID: NCT00880633 Completed - Clinical trials for Periampullary Neoplasms

Endoscopic Ultrasound Staging of Periampullary Neoplasms: Retrospective

Start date: April 2007
Phase: N/A
Study type: Observational

The purpose of this retrospective study is to determine the degree to which a biliary stent affects EUS staging accuracy of ampullary tumors.

NCT ID: NCT00880568 Completed - Neoplasms Clinical Trials

Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)

Start date: April 2009
Phase: Phase 1
Study type: Interventional

This study determines recommended clinical dose, to evaluate the safety, tolerability and pharmacokinetics of MK-1496 in patients with locally advanced and/or metastatic solid tumors who have failed standard therapy or for whom no standard therapy exists, in two dosing schedules in Japan.

NCT ID: NCT00880074 Completed - Malignant Neoplasm Clinical Trials

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

Start date: April 9, 2009
Phase: Phase 1
Study type: Interventional

This clinical trial studies fluorine F-18 fluorothymidine (FLT)-positron emission tomography (PET) in predicting response to chemotherapy in patients with advanced malignancies. FLT solution can help locate cancer cells inside the body. Diagnostic procedures, such as FLT-PET, may help find tumors and measure a patient's response to treatment.

NCT ID: NCT00879905 Completed - Clinical trials for Advanced Solid Malignancies

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Start date: May 2009
Phase: Phase 1
Study type: Interventional

This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.

NCT ID: NCT00879684 Completed - Cancer Clinical Trials

Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

Start date: January 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.

NCT ID: NCT00879554 Completed - Cancer Clinical Trials

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

CVX-045-101
Start date: February 2007
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.

NCT ID: NCT00878423 Completed - Clinical trials for Metastatic Solid Tumors

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Start date: May 2008
Phase: Phase 1
Study type: Interventional

AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options. The preferred dose of AT13387 will be identified according to the side effects experienced at different dose levels.

NCT ID: NCT00877136 Completed - Clinical trials for Hepatocellular Carcinoma

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

Start date: February 2009
Phase:
Study type: Observational

This is an interdisciplinary study that falls into the Humanitarian Use Device category. There are no hypotheses to be tested in this treatment protocol. The study has the following objectives: 1. Provide supervised access to treatment with TheraSphere® to eligible patients with primary cancer to the liver who are not surgical resection candidates. 2. Evaluate patient experience and toxicities associated with TheraSphere® treatment. 3. Measure tumor response rates

NCT ID: NCT00875433 Completed - Neoplasms Clinical Trials

Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

Start date: March 2009
Phase: Phase 2
Study type: Interventional

A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers. Cancers studied will include glioblastoma and cancers which have spread to the brain (metastases).